Skip to Content Skip to Content

Perelman School of Medicine

Visit the School's Site
Reset All Filters
2719 Results
With second FDA approval, CAR-T’s transformative power multiplies
With second FDA approval, CAR-T’s transformative power multiplies

With second FDA approval, CAR-T’s transformative power multiplies

After last year’s approval to treat pediatric lymphoma, the latest indication will expand the number of patients that can be treated with personalized cell therapy almost tenfold.

Katherine Unger Baillie

The path through Penn Medicine
MedSchool

The path through Penn Medicine

Medical students can commiserate with each other over the experience of med school and share a level of empathy and understanding with one another. But the reality of being a med student is a unique experience for everyone. Two students who were profiled in their first and second years of training reflect on their third year at the Perelman School of Medicine. 

Penn Today Staff

Two faculty members elected to National Academy of Sciences
Berger-Goldberg

Shelley Berger and Karen Goldberg

Two faculty members elected to National Academy of Sciences

Shelly Berger and Karen Goldberg are among 84 new members elected to the National Academy of Sciences, one of the highest honors for a scientist.

Katherine Unger Baillie , Karen Kreeger , Ali Sundermier

Healthy T cells have a fighting chance for cell therapy
t-cell

Healthy T cells have a fighting chance for cell therapy

Patients with chronic lymphocytic leukemia (CLL) who have a healthy amount of T cells prior to treatment (“early memory” T cells) responded positively to CAR T therapy, highlighting a powerful biomarker for successful therapies for that specific type of leukemia. 

Penn Today Staff

A potential new weapon in the battle against addiction
Research from Penn’s Heath Schmidt revealed that drugs already approved by the FDA to treat diabetes and obesity may reduce cocaine relapse and help addicted people break the habit

The green fluorescent ‘dots’ above show where Exendin-4, an FDA-approved drug used to treat diabetes and obesity, ends up in the brain. The drug activates receptors for glucagon-like peptide 1 or GLP-1, a hormone that reduces food intake. The blue and red coloring indicate neurons and astrocytes, respectively.

A potential new weapon in the battle against addiction

New research revealed that FDA-approved drugs to treat diabetes and obesity may reduce cocaine relapse and help addicts break the habit. Such medications work by targeting receptors for glucagon-like peptide 1, a hormone in the brain.

Michele W. Berger